Alzheimer’s disease pulls at the heart strings. Like many degenerative diseases, it’s easily represented by a ticking time bomb that brings devastation to patients, caregivers and loved ones. With many clinical trials failing to meet primary endpoints, it can be difficult for those both treating and affected by Alzheimer’s to wonder what the future will bring.
Study 201 of the experimental anti-amyloid beta protofibril antibody BAN2401 brings encouraging news to the Alzheimer’s community. Preliminary results of the Phase II study have shown significance in slowing progression on composite disease scales and reduction of amyloid accumulated in the brain as early as six months following treatment initiation. This is also a great example of how newer trial designs are being used to help speed up the drug development pathway and identify potentially successful regimens!
With the Alzheimer’s community long overdue for a win, this disease-modifying therapy is certainly one to keep an eye on!